NexGel
NXGL

$2.52

0.79%

Market Cap: $15.9M

About: NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.

Employees: 19

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

0.1% more ownership

Funds ownership: 2.44% [Q1] → 2.54% (+0.1%) [Q2]

8% less funds holding

Funds holding: 12 [Q1] → 11 (-1) [Q2]

17% less capital invested

Capital invested by funds: $413K [Q1] → $342K (-$70.6K) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NXGL.

See Analyst Rankings

Financial journalist opinion

NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript

NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer, President and Director Adam Drapczuk - Chief Financial Officer Conference Call Participants William Odenthal - COVA Capital Partners Eric Ramos - Titan Capital Management Operator Good afternoon. I will be your conference operator today.

NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript

NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million

LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the 2024 third and fourth quarter of $2.2 million and $2.6 million, respectively.

NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million

NEXGEL to Report Second Quarter 2024 Financial Results on August 14th

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.

NEXGEL to Report Second Quarter 2024 Financial Results on August 14th

NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal

The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments

NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal

NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively

LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024.

NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America

LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. Histasolv®, sold as DAOSIN® in Europe, is Europe's number one selling Diamine Oxidase (‘DAO') enzyme supplement generating well over $10 million in annualized revenue to treat histamine food intolerance, which can cause migraines and headaches, gut issues, and skin conditions. Headquartered in Germany, STADA is one of the fastest growing top ten companies in consumer healthcare and the fourth largest manufacturer in this segment in Europe.

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America

NEXGEL Acquires International Beauty Brand, Silly George

Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the acquisition of Silly George , an international beauty company with specialty in eye and eyelash consumer products and a revenue run rate of approximately $2 million.

NEXGEL, Inc. (NXGL) Q1 2024 Earnings Call Transcript

NEXGEL, Inc. (NASDAQ:NXGL ) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon, everyone. My name is Beau, and I will be your conference operator today.

NEXGEL, Inc. (NXGL) Q1 2024 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

LANGHORNE, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

See News Rankings